ContraFect Corp Revenue and Competitors

ContraFect is a biotechnology company pioneering the use of monoclonal antibodies to treat life-threatening infectious diseases. Our scientific approach is based on the following principles: Use Monoclonal Antibodies (MABs) for the treatment of life threatening infectious diseases bacterial as well as viral Transition from conventional mono-therapy to a combinatorial approach using multi-therapy antibody treatment Address the growing challenge of drug resistance and therapy escape mechanisms used by pathogens by applying monoclonal antibody multi-therapy approaches, or by choosing novel targets that are immune to the pathogens escape mechanisms Apply ContraFect's unique approach to develop treatments to two of today's current major threats to public health: MRSA a bacterial hospital or community acquired infection, that is antibiotic resistant and has become the 8th leading cause of death in the United States Influenza a viral-based infection that might pose the greatest pandemic threat to the worlds public health, as demonstrated in the current Swine Flu outbreak